CN104474304A - Traditional Chinese medicine composition for preventing or treating myocardial infarction - Google Patents

Traditional Chinese medicine composition for preventing or treating myocardial infarction Download PDF

Info

Publication number
CN104474304A
CN104474304A CN201410744702.0A CN201410744702A CN104474304A CN 104474304 A CN104474304 A CN 104474304A CN 201410744702 A CN201410744702 A CN 201410744702A CN 104474304 A CN104474304 A CN 104474304A
Authority
CN
China
Prior art keywords
parts
chinese medicine
radix
medicine composition
myocardial infarction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201410744702.0A
Other languages
Chinese (zh)
Inventor
崔合芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201410744702.0A priority Critical patent/CN104474304A/en
Publication of CN104474304A publication Critical patent/CN104474304A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/424—Gynostemma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8988—Gastrodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese medicine composition for preventing or treating myocardial infarction, relating to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine materials: astragalus, salvia miltiorrhiza, rhizoma gastrodiae, safflowers, cattail pollen, gynostemma pentaphylla, olibanum, tea, leeches, long-noded pit vipers, angelica sinensis, eucommia ulmoides, radix paeoniae rubra, flos sophorae, snakegourd peel, hawthorns, peach kernels and liquorice. The traditional Chinese medicine composition disclosed by the invention is not only capable of promoting blood circulation, invigorating blood circulation to remove blood stasis as well as softening blood vessels, but also durable in taking effects, free of side effects, stable in curative effect and easy to popularize.

Description

The Chinese medicine composition of a kind of prevention or treatment myocardial infarction
Technical field
The present invention relates to technical field of Chinese medicine, be specifically related to the Chinese medicine composition of a kind of prevention or treatment myocardial infarction.
Background technology
Myocardial infarction (myocardialinfarction) is coronary occlusion, blood flow ceases, makes part cardiac muscle, because of serious persistency ischemia, local necrosis occur.Have acutely and comparatively lasting retrosternal pain clinically, heating, leukocytosis, erythrocyte sedimentation rate are accelerated, and serum cardiac enzyme activity increases and Progressive symmetric erythrokeratodermia ECG Change, and arrhythmia, shock or heart failure can occur.All older patients suffer a shock suddenly, severe arrhythmia, heart failure, the performances such as upper abdomen distending pain or vomiting and the not bright person of reason, or original hypertension and blood pressure reduces suddenly and can the person of seeking without reason, there is shock but get rid of the reason persons such as hemorrhage in Post operation, all should expect the possibility of myocardial infarction.In addition older patients has heavier and lasting uncomfortable in chest or chest pain person more of a specified duration, even if electrocardiogram atypism changes, also should consider the possibility of primary disease, all first should press acute myocardial infarction process, and repeatedly carry out Ecg and serum cardiac enzymatic determination in a short time, to determine diagnosis.Acute myocardial infarction is unexpected, should prevent early, find early, and early treatment.
The Western medicine for the treatment of myocardial infarction mainly contains: aspirin, clopidogrel, lotensin, metoprolol etc.
Also the Chinese medicine of part treat primary disease is had, as: patent of invention CN201410464071 discloses a kind of Chinese medicine preparation for the treatment of myocardial infarction, is prepared from by following raw materials in part by weight medicine: Radix Glycyrrhizae 2-6, Flos Caryophylli 20-45, Stigma Croci 2-6, Pollen Typhae 20-45, Fructus Trichosanthis 20-45, Radix Curcumae 6-15, Fructus Hordei Germinatus 20-45, Lignum Dalbergiae Odoriferae 2-6, Radix Ophiopogonis 6-15, Borneolum Syntheticum 0.05-0.5.Medicine source is easy to get, and medical material is with low cost, can relieve patient ' s burden, and selected materials is all Chinese medicine material, without any side effects.Patent of invention CN201410304781 discloses a kind of Chinese medicine preparation for the treatment of myocardial infarction, its raw medicinal material respectively: Radix Ginseng 6 parts, Radix Aconiti Lateralis Preparata 6 parts, Ramulus Cinnamomi 12 parts, Oletum Trogopterori 10 parts, Pollen Typhae 10 parts, Herba Asari 6 parts, Rhizoma Corydalis 10 parts, Radix Salviae Miltiorrhizae 10 parts, Pericarpium Papaveris 12 parts, Radix Glycyrrhizae Preparata 6 parts, the Radix Astragali 10 parts.
The treatment of above medicine to myocardial infarction has certain effect, but there is large or slow, that curative effect the is unstable shortcoming that takes effect of side effect, in order to overcome above-mentioned shortcoming, the present invention is in conjunction with modern Chinese medicine theory of development, from improving curative effect of medication, reducing the angle of side effect, process carries out screening extraction to Chinese medicine ingredients and/or compatibility obtains this medicament.
Summary of the invention
The object of the present invention is to provide the Chinese medicine composition of a kind of prevention more safely and effectively or treatment myocardial infarction.
The object of the present invention is achieved like this:
A Chinese medicine composition for prevention or treatment myocardial infarction, is prepared from by the Chinese crude drug of following weight portion: Radix Astragali 8-15 part, Radix Salviae Miltiorrhizae 17-24 part, Rhizoma Gastrodiae 6-12 part, Flos Carthami 8-15 part, Pollen Typhae 25-30 part, Herb Gynostemmae Pentaphylli 15-20 part, Olibanum 15-20 part, Folium Camelliae sinensis 25-30 part, Hirudo 12-18 part, Agkistrodon 5-10 part, Radix Angelicae Sinensis 18-25 part, Cortex Eucommiae 12-18 part, Radix Paeoniae Rubra 18-24 part, Flos Sophorae 25-30 part, Pericarpium Trichosanthis 25-30 part, Fructus Crataegi 25-30 part, Semen Persicae 16-23 part, Radix Glycyrrhizae 25-30 part.
Preferably, the Chinese medicine composition of described prevention or treatment myocardial infarction, is prepared from by the Chinese crude drug of following weight portion: the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 20 parts, 10 parts, Rhizoma Gastrodiae, 12 parts, Flos Carthami, Pollen Typhae 27 parts, Herb Gynostemmae Pentaphylli 17 parts, Olibanum 18 parts, Folium Camelliae sinensis 28 parts, Hirudo 15 parts, Agkistrodon 8 parts, Radix Angelicae Sinensis 20 parts, the Cortex Eucommiae 15 parts, Radix Paeoniae Rubra 20 parts, 27 parts, Flos Sophorae, Pericarpium Trichosanthis 27 parts, Fructus Crataegi 27 parts, 20 parts, Semen Persicae, 27 parts, Radix Glycyrrhizae.
The Chinese medicine composition of described prevention or treatment myocardial infarction is oral formulations.
Again further preferably, the Chinese medicine composition of described prevention or treatment myocardial infarction is oral liquid, granule, tablet or capsule.
Found by clinical application research, the pharmaceutical composition be prepared from by above-mentioned Chinese crude drug obtains satisfied curative effect in prevention or treatment myocardial infarction.Therefore, second object of the present invention is to provide a kind of new medical use, and namely above-mentioned Chinese medicine composition prevents in preparation or treats the application in the Chinese medicine of myocardial infarction.
According to Chinese medicine Historical Data Data About, above-mentioned Chinese crude drug has following pharmacologically active and function cures mainly:
The Radix Astragali: there is invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, effect of expelling pus and promoting granulation.Weak for the deficiency of vital energy, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, carbuncle difficulty is burst, and burst for a long time and do not hold back, blood deficiency and yellow complexion, interior-heat is quenched one's thirst.Select the dry root of leguminous plant Radix Astagali or Radix Astragali.
Radix Salviae Miltiorrhizae: blood circulation promoting and blood stasis dispelling, removing heat from blood eliminating carbuncle, nourishing blood to tranquillize the mind.Cure mainly menoxenia, amenorrhea dysmenorrhea ， lumps in the chest and abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, angina pectoris.Select the dry root and rhizome of labiate Radix Salviae Miltiorrhizae.
Rhizoma Gastrodiae: suppressing the hyperactive liver to relieve the wind syndrome, wind-expelling pain-stopping, has calmness, analgesia, anticonvulsant action; Can cerebral blood flow be increased, reduce cerebral vascular resistance, light contraction cerebrovascular, increase coronary vasodilator flow; Can reduce blood pressure, decreased heart rate, has protective effect to myocardial ischemia; The headache of blood deficiency liver-wind stirring up internally, dizzy, dizzy, migraine and general headache, numb limbs and tense tendons, hemiplegia that wind-phlegm causes can be treated.Also can be used for infantile convulsion, epilepsy, tetanus.Select the dry tuber of the orchid family Gastrodia plant.
Flos Carthami: promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain.For amenorrhea, dysmenorrhea, lochia, lump in the abdomen mass in the abdomen, traumatic injury, be suitable for various varicosis, peripheral neuritis, blood circulation is bad, lower limb numbness or the congestion such as livid purple.Select the dried floral of feverfew Flos Carthami Carthamus tinctorius L..
Pu is yellow: cooling blood for hemostasis, blood circulation promoting and blood stasis dispelling, cure mainly haematemesis; Spitting of blood; Epistaxis; Standby dysentery; Have blood in stool; Metrorrhagia; Traumatic hemorrhage; Trusted subordinate's pain; Amenorrhea is suffered from abdominal pain; Puerperal the stasis of blood pain; Dysmenorrhea; Tumbling and swelling; Blood strangury and dry pain; Leukorrhagia; Congenital deformity of the tongue; Aphtha; Ting ear; Uncontrolled urination is itched.Select the dry pollen of Typhaceae plant Typha angustifolia Herba Typhae, typha orientalis or congener.
Herb Gynostemmae Pentaphylli: energy QI invigorating, calms the nerves, blood pressure lowering, heat-clearing and toxic substances removing, eliminating phlegm and stopping cough, and strong the intestines and stomach enhancement is digested and assimilated, protected heart Bao Mai, regulating lipid and reducing weight.Cucurbitaceae is selected to overgrow the dry Herb of herbaceous plant Herb Gynostemmae Pentaphylli and multiple congener.
Olibanum: regulating qi and activating blood, analgesic therapy, chases after poison, has strong bacteriostasis, and effectively can kill infusorian.Control coagulation of QI-blood, trusted subordinate's pain, carbuncle pyogenic infections from tumour or sore, traumatic injury, dysmenorrhea, postnatal blood stasis twinge.Select the scented resin containing volatile oil of olive subject plant Olibanum wood (Boswellia thurifera or Boswellia sacra) output.
Folium Camelliae sinensis: the effects such as tool antioxidation, anti-halmatogenesis, antitumor, reduction Blood Cholesterol and low-density ester gp content, the rising of suppression blood pressure, suppression platelet aggregation, antibacterial, anti-product allergy.
Hirudo contains hirudin, can delay and hinder blood coagulation, thus having blood coagulation resisting function.There is the effect such as treatment apoplexy, hypertension, the clear stasis of blood, amenorrhea, traumatic injury.At control cardiovascular and cerebrovascular disease and anticancer aspect, there is specially good effect.
Agkistrodon: dispel the wind, dredging collateral, relieving convulsion.For rheumatoid arthritis stubborn, numbness contracture, middle air port is askew, hemiplegia, tic spasm, tetanus, leprosy scabies, scrofula malignant boil.Viperidae animal Agkistrodon or Elapidae animal Agkistrodon snakelet etc. is selected to remove the entirety of internal organs.
Radix Angelicae Sinensis: hematonic; Enrich blood, invigorate blood circulation, menstruction regulating and pain relieving, moisturize laxation, cure mainly all cards of blood deficiency; Menoxenia; Amenorrhea; Dysmenorrhea; Lump in the abdomen knot is poly-; Metrorrhagia; Asthenia cold abdominalgia; Flaccidity syndrome and arthralgia syndrome; Numbness of the skin; Dryness of the intestine dyschezia; Heavy after bloody dysentery; Ulcer sores; Injury from falling down.Select the dry root of umbelliferae angelica.
The Cortex Eucommiae: blood pressure lowering, invigorating the liver and kidney, bone and muscle strengthening, antiabortive gas.Be applicable to: hypertension, vertigo, apoplexy sequela, chronic renal disease, poliomyelitis etc.Select the dry bark of the Eucommiaceae plant Cortex Eucommiae.
Radix Paeoniae Rubra: clearing away heat and cooling blood, eliminating stasis to stop pain.For maculae caused by violent heat pathogen, conjunctival congestion and swelling pain, hypochondriac pain due to stagnation of liverQI, amenorrhea dysmenorrhea, lump in the abdomen is suffered from abdominal pain, injury from falling down.Select the dry root of ranunculaceae plant Radix Paeoniae Rubra or river Radix Paeoniae Rubra.
Flos Sophorae: the function of cooling blood for hemostasis, purging liver-fire.The property of Flos Sophorae bitter cold is comparatively strong, is longer than purging liver-fire, clearing away heat and cooling blood.Be used for bleeding due to blood-heat, liver-heat conjunctival congestion, have a headache dizzy, sore swells and ache.Select the dried floral of leguminous plant Chinese scholartree.
Pericarpium Trichosanthis: Qinghua heat-phlegm, promoting the circulation of QI the chest stuffiness relieving.For phlegm-heat cough, hypochondriac pain uncomfortable in chest.Select the dry mature skin of cucurbitaceous plant Fructus Trichosanthis or trichosanthes rosthornii Harms.
Fructus Crataegi: sour in the mouth is warm in nature, QI and blood is also walked, blood stasis dispelling and do not hinder fresh blood, the stagnant gas of row and do not hinder healthy energy, is applied to meat stagnation card, the stagnant stomachache chest pain of dysentery stomachache, colicky, the stasis of blood, lochiorrhea, dysmenorrhea, spits blood, has blood in stool.Modern alone this product preparation for treating cardiovascular disease, bacillary dysentery etc., all have good therapeutic effect, have blood fat reducing, blood pressure lowering, anti-brain blood and mechanism of action thereof.
Semen Persicae: blood stasis removing and clots absorbing; Moisturize laxation.Main warp closes; Lump in the abdomen; Calentura blood-retention; Migratory arthralgia; Malaria; Traumatic injury; Swelling and pain due to blood stasis; The dry constipation of blood.Select the seed of rosaceous plant Fructus Persicae or Prunus davidiana.
Radix Glycyrrhizae: raw with cooler, can eliminating fire and detoxication, relieving spasm to stop pain; Process with partially warm, can fall apart exterior cold, invigorating the spleen and replenishing QI.In addition, Radix Glycyrrhizae is also good at being in harmonious proportion the property of medicine, separates the poison of hundred medicines.Select the dry rhizome of glycyrrhizic legume.
Above-mentioned each Chinese crude drug is prepared into the preparation method of compound oral liquid of the present invention, comprise the steps: to take ingredients in prescription by weight, merge, decoct with water twice, collecting decoction, when being evaporated to 70 DEG C, relative density is 1.15-1.20, adds ethanol and makes the percent by volume of alcohol content reach 75-85%, stirs, leave standstill, filter, during filtrate reduced in volume to 70 DEG C, relative density is 1.10-1.20 and reclaims ethanol to obtain concentrated solution, is added water by concentrated solution and auxiliaries becomes oral liquid.
Compared with prior art, tool of the present invention has the following advantages and progress significantly: (1) good effect, is found by a large amount of clinical practices, the Chinese medicine composition that the present invention relates to can not only blood circulation promoting, promoting blood circulation to remove blood stasis, vessel softening, and persistent, have no side effect, efficacy consolidation; Further, lot of experiments research display, Most patients takes medicine of the present invention and namely occurs obvious curative effects 1 course for the treatment of.(2) safety is high, and because medicine of the present invention is prepared from by adopting Chinese medicine material, patient medication is safer.
Detailed description of the invention
Embodiment 1 prepares the Chinese medicine composition oral liquid of prevention or treatment myocardial infarction
Crude drug prescription: the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 20 parts, 10 parts, Rhizoma Gastrodiae, 12 parts, Flos Carthami, Pollen Typhae 27 parts, Herb Gynostemmae Pentaphylli 17 parts, Olibanum 18 parts, Folium Camelliae sinensis 28 parts, Hirudo 15 parts, Agkistrodon 8 parts, Radix Angelicae Sinensis 20 parts, the Cortex Eucommiae 15 parts, Radix Paeoniae Rubra 20 parts, 27 parts, Flos Sophorae, Pericarpium Trichosanthis 27 parts, Fructus Crataegi 27 parts, 20 parts, Semen Persicae, 27 parts, Radix Glycyrrhizae.
Preparation method: the medical material taking above-mentioned recipe quantity merges, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 2h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.08MPa, relative density is 1.15 when being evaporated to 70 DEG C at 70 DEG C, adds 95% (v/v) ethanol and makes alcohol content reach 75% (v/v), stir, hold over night, filter, under 0.08MPa, 65 DEG C of conditions, concentrating under reduced pressure becomes filtrate is 1.15g/mL to relative density when 65 DEG C, adds water and sucrose is mixed with oral liquid.
Embodiment 2 prepares the Chinese medicine composition oral liquid of prevention or treatment myocardial infarction
Crude drug prescription: the Radix Astragali 8 parts, Radix Salviae Miltiorrhizae 17 parts, 6 parts, Rhizoma Gastrodiae, 8 parts, Flos Carthami, Pollen Typhae 25 parts, Herb Gynostemmae Pentaphylli 15 parts, Olibanum 15 parts, Folium Camelliae sinensis 25 parts, Hirudo 12 parts, Agkistrodon 5 parts, Radix Angelicae Sinensis 18 parts, the Cortex Eucommiae 12 parts, Radix Paeoniae Rubra 18 parts, 25 parts, Flos Sophorae, Pericarpium Trichosanthis 25 parts, Fructus Crataegi 25 parts, 16 parts, Semen Persicae, 25 parts, Radix Glycyrrhizae.
Preparation method: the medical material taking above-mentioned recipe quantity merges, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 2h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.08MPa, relative density is 1.15 when being evaporated to 70 DEG C at 70 DEG C, adds 95% (v/v) ethanol and makes alcohol content reach 85% (v/v), stir, hold over night, filter, under 0.08MPa, 65 DEG C of conditions, concentrating under reduced pressure becomes filtrate is 1.15g/mL to relative density when 65 DEG C, adds water and sucrose is mixed with oral liquid.
Embodiment 3 prepares the Chinese medicine composition oral liquid of prevention or treatment myocardial infarction
Crude drug prescription: the Radix Astragali 15 parts, Radix Salviae Miltiorrhizae 24 parts, 12 parts, Rhizoma Gastrodiae, 15 parts, Flos Carthami, Pollen Typhae 30 parts, Herb Gynostemmae Pentaphylli 25 parts, Olibanum 20 parts, Folium Camelliae sinensis 30 parts, Hirudo 18 parts, Agkistrodon 10 parts, Radix Angelicae Sinensis 25 parts, the Cortex Eucommiae 18 parts, Radix Paeoniae Rubra 24 parts, 30 parts, Flos Sophorae, Pericarpium Trichosanthis 30 parts, Fructus Crataegi 30 parts, 23 parts, Semen Persicae, 30 parts, Radix Glycyrrhizae.
Preparation method: the medical material taking above-mentioned recipe quantity merges, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 2h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.08MPa, relative density is 1.20 when being evaporated to 70 DEG C at 70 DEG C, adds 95% (v/v) ethanol and makes alcohol content reach 80% (v/v), stir, hold over night, filter, under 0.08MPa, 65 DEG C of conditions, concentrating under reduced pressure becomes filtrate is 1.15g/mL to relative density when 65 DEG C, adds water and sucrose is mixed with oral liquid.
Embodiment 4 prepares the Chinese medicine composition oral liquid of prevention or treatment myocardial infarction
Crude drug prescription: the Radix Astragali 12 parts, Radix Salviae Miltiorrhizae 20 parts, 10 parts, Rhizoma Gastrodiae, 12 parts, Flos Carthami, Pollen Typhae 25 parts, Herb Gynostemmae Pentaphylli 18 parts, Olibanum 18 parts, Folium Camelliae sinensis 25 parts, Hirudo 16 parts, Agkistrodon 5 parts, Radix Angelicae Sinensis 20 parts, the Cortex Eucommiae 15 parts, Radix Paeoniae Rubra 22 parts, 28 parts, Flos Sophorae, Pericarpium Trichosanthis 28 parts, Fructus Crataegi 28 parts, 23 parts, Semen Persicae, 28 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
The animal toxicity test of embodiment 5 Chinese medicine oral liquid of the present invention
(1) test drug: Chinese medicine oral liquid obtained by embodiment of the present invention 1-4.Test animal used: regular grade NIH mice, body weight 21g ± 5g, male and female half and half, female mice is all without pregnant; SD rat, original body mass 215g ± 7g, male and female half and half, female rats is all without pregnant.
(2) acute toxicity test
Application mice carries out acute toxicity testing and shows: the above-mentioned test drug of mouse stomach, under 500g crude drug/kg dosage, after administration, mice occurs that light activity reduces, 1 hours recovers normal, Continuous Observation 7 days after administration, none dead mouse, and overall health of patients, diet, take the photograph water, urine and body weight increase all normal.Experimental result shows: the maximum dosage-feeding of mouse stomach Chinese medicine of the present invention is 500g crude drug/kg/d(LD 50> 500g crude drug/kg).Chinese medicine preparation clinical application every day total amount of the present invention is 0.12g crude drug/kg/d; By weighing machine, the dosis tolerata of mouse stomach Chinese medicine preparation of the present invention is 4167 times of clinical patient.Point out this medicine acute toxicity extremely low, clinical drug safety.
(3) long term toxicity test
Select SD rat, give the Chinese medicine oral liquid of the present invention of Three doses: 21.6g crude drug/kg, 7.2g crude drug/kg, 2.4g crude drug/kg(per weight dosage is by 20 times of calculating of clinical application amount, and clinical application amount is according to Pharmacopoeia of the People's Republic of China version in 2010).Every day gavage once, continuous 90 days, after last administration 24 hours respectively group live and kill 1/2 animal (male and female half and half), all the other 1/2 animals continue that observations are alive after 2 weeks kills.Duration of test observes outward appearance, general behavior, food ration, the body weight change of animal; Within after administration 90 days, within 2 weeks, carry out the index checking such as hematology's (RBC, HB, reticulocyte, PLT, CT, WBC and classification) and blood biochemical (AST, ALT, ALP, Glu, BUN, Crea, TP, T.BIL, ALB, CHOL), urine biochemistry, organ coefficient, histopathology with drug withdrawal.
Result of the test shows: Chinese medicine preparation of the present invention is good at high, medium and low dosage treated animal general state, and outward appearance sign, behavioral activity, food-intake and body weight increase change all without exception; Three dosage groups and matched group hematological examination, blood biochemical analysis, urine biochemical analysis all in normal range, without significant difference between group; Each group of main organs histopathological examination shows no obvious abnormalities.These parameters drug withdrawal also had no change after 2 weeks.This test dosage is respectively 180,60,20 times of clinical medicine dose, according to result of the test: Chinese medicine preparation of the present invention has no significant effect rat in high, medium and low three dosage (21.6g crude drug/kg, 7.2g crude drug/kg, 2.4g crude drug/kg) administration in continuous 90 days, without clear and definite toxicity target organ and sensitive indicator, convalescent period observation also has no retardance toxic reaction, points out the dose safety of Chinese medicine preparation clinical practice of the present invention very high.
Embodiment 6, clinical effectiveness are tested
1, experimenter's data
Experimenter is all from certain institute of traditional Chinese medicine of city Patients With Myocardial Infarction that year December is accepted for medical treatment in May, 2011 to 2013 or find that there is the patient suffering from myocardial infarction sign, (experimenter shows as: on the basis of coronary atherosclerosis concurrent atheromatous plaque break, hemorrhage, Endovascular thrombosis, endarterium bleed bottom or tremulous pulse fixed spasm, make tube chamber that lasting obturation partially or completely occur rapidly.) therefrom select be applicable to test patient 124 example, wherein man 68 example, age 45-69 year, female 56 example, age 50-72 year.According to ill weight, age, sex, experimenter is divided into 4 groups, is numbered matched group respectively, test 1 group, test 2 groups, test 3 groups.
2, test method
(1) matched group takes metoprolol (AstraZeneca pharmaceutical Co. Ltd, the accurate word H32025391 of traditional Chinese medicines), every day 2 times, each 75mg.
(2) 1,2,3 group of Chinese medicine oral liquid taken respectively obtained by embodiment of the present invention 1-3 is tested, every day 2 times, each 20ml.
Within (3) 3 weeks, be a course for the treatment of, treat 3 courses for the treatment of continuously.The situation such as health, untoward reaction of record patient simultaneously.
3, evaluation criterion
(1) cure: Atherosclerotic Vessels: Changes Observed during Coronary disappears, Endovascular thrombosis disappears, and the symptoms such as endarterium bleed bottom or tremulous pulse fixed spasm disappear completely, and tube chamber is without blocking.
(2) effective: Atherosclerotic Vessels: Changes Observed during Coronary reduces, Endovascular thrombosis reduces, and the transference cures such as endarterium bleed bottom or tremulous pulse fixed spasm, need continual cure.
(3) invalid: Atherosclerotic Vessels: Changes Observed during Coronary is without reduction, Endovascular thrombosis without reduction, and the symptoms such as endarterium bleed bottom or tremulous pulse fixed spasm are without any improvement, and tube chamber still blocks or has inaccessible danger.
(4) patient self sensation and the situation of adjustment.
(5) untoward reaction.
4, result of the test
(1) patient body feels to there is significant difference, and take Western medicine patient complexion, spirit do not improve significantly, even if enter sleep under the effect of medicine, sleep quality is also bad, and having dizzy spells in awake back, does not have spirit; Take the experimenter of oral liquid of the present invention after a course for the treatment of, blood pressure is normal, and complexion and spirit are all improved, and have rosy cheeks, and spirit foot, sleep quality is good.
(2) result of the test statistical analysis
After test all terminates, statistical analysis is carried out, in table 1 to test data sheet data.
Table 1 result of the test statistical analysis table
5, conclusion (of pressure testing)
As can be seen from the result of the test of two aspects, take the patient body sensation of Chinese medicine preparation of the present invention significantly better than matched group; Average cure rate (68.8%) is 3.5 times of matched group, and average total effective rate (94.6%) is higher than matched group by 26.9%, and matched group has 9 routine untoward reaction, 3 none routine untoward reaction of embodiment group.Therefore, as can be seen from these data, Chinese medicine preparation of the present invention (especially embodiment 1) has very significant technical advantage, obtains beat all technological achievement.

Claims (7)

1. a Chinese medicine composition for prevention or treatment myocardial infarction, is characterized in that being prepared from by the Chinese crude drug of following weight portion: Radix Astragali 8-15 part, Radix Salviae Miltiorrhizae 17-24 part, Rhizoma Gastrodiae 6-12 part, Flos Carthami 8-15 part, Pollen Typhae 25-30 part, Herb Gynostemmae Pentaphylli 15-20 part, Olibanum 15-20 part, Folium Camelliae sinensis 25-30 part, Hirudo 12-18 part, Agkistrodon 5-10 part, Radix Angelicae Sinensis 18-25 part, Cortex Eucommiae 12-18 part, Radix Paeoniae Rubra 18-24 part, Flos Sophorae 25-30 part, Pericarpium Trichosanthis 25-30 part, Fructus Crataegi 25-30 part, Semen Persicae 16-23 part, Radix Glycyrrhizae 25-30 part.
2. the Chinese medicine composition of prevention according to claim 1 or treatment myocardial infarction, is characterized in that being prepared from by the Chinese crude drug of following weight portion: the Radix Astragali 8 parts, Radix Salviae Miltiorrhizae 17 parts, 6 parts, Rhizoma Gastrodiae, 8 parts, Flos Carthami, Pollen Typhae 25 parts, Herb Gynostemmae Pentaphylli 15 parts, Olibanum 15 parts, Folium Camelliae sinensis 25 parts, Hirudo 12 parts, Agkistrodon 5 parts, Radix Angelicae Sinensis 18 parts, the Cortex Eucommiae 12 parts, Radix Paeoniae Rubra 18 parts, 25 parts, Flos Sophorae, Pericarpium Trichosanthis 25 parts, Fructus Crataegi 25 parts, 16 parts, Semen Persicae, 25 parts, Radix Glycyrrhizae.
3. the Chinese medicine composition of prevention according to claim 1 or treatment myocardial infarction, is characterized in that being prepared from by the Chinese crude drug of following weight portion: the Radix Astragali 15 parts, Radix Salviae Miltiorrhizae 24 parts, 12 parts, Rhizoma Gastrodiae, 15 parts, Flos Carthami, Pollen Typhae 30 parts, Herb Gynostemmae Pentaphylli 25 parts, Olibanum 20 parts, Folium Camelliae sinensis 30 parts, Hirudo 18 parts, Agkistrodon 10 parts, Radix Angelicae Sinensis 25 parts, the Cortex Eucommiae 18 parts, Radix Paeoniae Rubra 24 parts, 30 parts, Flos Sophorae, Pericarpium Trichosanthis 30 parts, Fructus Crataegi 30 parts, 23 parts, Semen Persicae, 30 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition of prevention according to claim 1 or treatment myocardial infarction, is characterized in that being prepared from by the Chinese crude drug of following weight portion: the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 20 parts, 10 parts, Rhizoma Gastrodiae, 12 parts, Flos Carthami, Pollen Typhae 27 parts, Herb Gynostemmae Pentaphylli 17 parts, Olibanum 18 parts, Folium Camelliae sinensis 28 parts, Hirudo 15 parts, Agkistrodon 8 parts, Radix Angelicae Sinensis 20 parts, the Cortex Eucommiae 15 parts, Radix Paeoniae Rubra 20 parts, 27 parts, Flos Sophorae, Pericarpium Trichosanthis 27 parts, Fructus Crataegi 27 parts, 20 parts, Semen Persicae, 27 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition of the prevention according to any one of claim 1-4 or treatment myocardial infarction, is characterized in that: described Chinese medicine composition is oral formulations.
6. the Chinese medicine composition of prevention according to claim 5 or treatment myocardial infarction, is characterized in that: described oral formulations is oral liquid, granule, tablet or capsule.
7. the Chinese medicine composition of the arbitrary described prevention of claim 1-4 or treatment myocardial infarction prevents in preparation or treats the application in the medicine of myocardial infarction.
CN201410744702.0A 2014-12-09 2014-12-09 Traditional Chinese medicine composition for preventing or treating myocardial infarction Withdrawn CN104474304A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410744702.0A CN104474304A (en) 2014-12-09 2014-12-09 Traditional Chinese medicine composition for preventing or treating myocardial infarction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410744702.0A CN104474304A (en) 2014-12-09 2014-12-09 Traditional Chinese medicine composition for preventing or treating myocardial infarction

Publications (1)

Publication Number Publication Date
CN104474304A true CN104474304A (en) 2015-04-01

Family

ID=52749005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410744702.0A Withdrawn CN104474304A (en) 2014-12-09 2014-12-09 Traditional Chinese medicine composition for preventing or treating myocardial infarction

Country Status (1)

Country Link
CN (1) CN104474304A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103212029A (en) * 2013-04-03 2013-07-24 王新程 Medicine for treating coronary heart diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103212029A (en) * 2013-04-03 2013-07-24 王新程 Medicine for treating coronary heart diseases

Similar Documents

Publication Publication Date Title
CN102772748B (en) Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof
CN101095768B (en) Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age
CN104258350A (en) Traditional Chinese medicine preparation for treating sick sinus syndrome and preparation method of traditional Chinese medicine preparation
CN103223069A (en) Traditional Chinese medicine composition for treating hepatitis
CN103721075B (en) A kind of Chinese medicine for post gynecologic operation and preparation method thereof
CN105412410A (en) Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy
CN103356952B (en) Chinese medicine composition for treating arrhythmia
CN102579610A (en) Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof
CN105311492A (en) Medicine for treating coronary atherosclerotic heart disease
CN104547798A (en) Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof
CN103285343A (en) Medicine for treating liver cancer and preparation method thereof
CN103169745A (en) Traditional Chinese medicine composition for treating hematuria and application thereof
CN103585414B (en) Pharmaceutical composition for treating sciatica and osteoporosis
CN102988779A (en) Chinese medicine composition for treating hypertensive nephropathy and preparation method and application of Chinese medicine composition
CN101884664B (en) Medicinal composition for preventing and treating rheumatoid arthritis and preparation method thereof
CN105727089A (en) Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome
CN101549140B (en) Traditional Chinese medicine composition for treating AIDS and preparation method thereof
CN105106758A (en) Traditional Chinese medicine composition for treating phlegm and blood stasis type dizziness
CN110772606A (en) Traditional Chinese medicine composition for preventing and treating ischemic stroke and preparation method thereof
CN1075727C (en) Shentong capsule and preparing method thereof
CN104474304A (en) Traditional Chinese medicine composition for preventing or treating myocardial infarction
CN103285360B (en) Traditional Chinese medicinal preparation for treating thromboangiitis obliterans, and preparation method thereof
CN110215474B (en) Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof
CN114869944B (en) Traditional Chinese medicine composition for treating atherosclerosis and preparation method thereof
CN102772665B (en) Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Ding Ximing

Inventor after: Lu Liqin

Inventor before: Cui Hefang

CB03 Change of inventor or designer information
WW01 Invention patent application withdrawn after publication

Application publication date: 20150401

WW01 Invention patent application withdrawn after publication